NanoViricides, Inc. reported that Mr. James Sapirstein has been duly appointed as an Independent Director to its Board of Directors. He will join the Board as of November 1, 2018, and will also become a member of the Board's Audit Committee, Nomination Committee, and Compensation Committee. In addition, the Board has also appointed Dr. Irach Taraporewala, CEO, as a Member of the Board. In 2012, Mr. Sapirstein became the CEO of Alliqua Biomedical at Alliqua, Inc. Thereafter, he served as CEO of Contravir Pharmaceuticals (CTRV) from March 2014 until October 2018. Mr. Sapirstein currently holds Board positions on Enochian Biosciences (ENOB), RespireRx Pharmaceuticals (RSPI) and the privately held company Leading Biosciences. Mr. Sapirstein's appointment as an Independent Director of the Board, as well as Dr. Taraporewala's appointment as a Member of the Board on November 1, 2018, are to be ratified by shareholder vote at the upcoming Annual General Meeting of the company, scheduled on November 30, 2018.